vs
Side-by-side financial comparison of Aardvark Therapeutics, Inc. (AARD) and ABEONA THERAPEUTICS INC. (ABEO). Click either name above to swap in a different company.
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for inflammatory, metabolic, and orphan diseases. It advances G-protein coupled receptor-targeting pipeline candidates, serving patient populations primarily in North America and global markets via R&D partnerships.
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of novel gene and cell therapies for life-threatening rare genetic diseases. Its pipeline addresses unmet medical needs, serving patient populations across North America and European markets with limited treatment alternatives.
Income Statement — Q4 2025 vs Q3 2025
| Metric |  |  |
|---|---|---|
| Revenue | $0 | $0 |
| Net Profit | $-17.6M | $-5.2M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | — |
| Revenue YoY | — | — |
| Net Profit YoY | — | 82.9% |
| EPS (diluted) | $-0.81 | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $0 | — | ||
| Q3 25 | $0 | $0 | ||
| Q2 25 | $0 | $400.0K | ||
| Q1 25 | $0 | — |
| Q4 25 | $-17.6M | — | ||
| Q3 25 | $-16.3M | $-5.2M | ||
| Q2 25 | $-14.4M | $108.8M | ||
| Q1 25 | $-9.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -5698.0% | ||
| Q1 25 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 27208.3% | ||
| Q1 25 | — | — |
| Q4 25 | $-0.81 | — | ||
| Q3 25 | $-0.75 | $-0.10 | ||
| Q2 25 | $-0.66 | $1.71 | ||
| Q1 25 | $-0.71 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $110.0M | $207.1M |
| Total DebtLower is stronger | — | $19.8M |
| Stockholders' EquityBook value | $106.6M | $171.2M |
| Total Assets | $117.2M | $231.1M |
| Debt / EquityLower = less leverage | — | 0.12× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $110.0M | — | ||
| Q3 25 | $126.3M | $207.1M | ||
| Q2 25 | $141.8M | $225.5M | ||
| Q1 25 | $151.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $19.8M | ||
| Q2 25 | — | $19.6M | ||
| Q1 25 | — | — |
| Q4 25 | $106.6M | — | ||
| Q3 25 | $122.4M | $171.2M | ||
| Q2 25 | $136.9M | $163.6M | ||
| Q1 25 | $150.7M | — |
| Q4 25 | $117.2M | — | ||
| Q3 25 | $133.2M | $231.1M | ||
| Q2 25 | $147.5M | $246.2M | ||
| Q1 25 | $157.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.12× | ||
| Q1 25 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-16.8M | $-21.2M |
| Free Cash FlowOCF − Capex | — | $-23.7M |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-16.8M | — | ||
| Q3 25 | $-16.1M | $-21.2M | ||
| Q2 25 | $-9.8M | $-18.8M | ||
| Q1 25 | $-11.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | $-16.1M | $-23.7M | ||
| Q2 25 | $-9.9M | $-21.7M | ||
| Q1 25 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -5421.3% | ||
| Q1 25 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 725.3% | ||
| Q1 25 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.17× | ||
| Q1 25 | — | — |
